IL2 and melanoma: In our previous study, we observed that a combination of local radiotherapy (RT), slow-release pegylated interleukin 2 (srIL-2) and antibody against cytotoxic T-lymphocyte antigen 4 (CTLA-4) induced regression of 1,000 mm3 B78 melanomas in some mice (10).